ECSP045076A - Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad - Google Patents

Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad

Info

Publication number
ECSP045076A
ECSP045076A EC2004005076A ECSP045076A ECSP045076A EC SP045076 A ECSP045076 A EC SP045076A EC 2004005076 A EC2004005076 A EC 2004005076A EC SP045076 A ECSP045076 A EC SP045076A EC SP045076 A ECSP045076 A EC SP045076A
Authority
EC
Ecuador
Prior art keywords
obesity
preparation
treatment
imidazol derivatives
compounds
Prior art date
Application number
EC2004005076A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045076A publication Critical patent/ECSP045076A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a derivados de imidazol sustituido que, según se encontró, suprimen el apetito e inducen la pérdida de peso. La invención suministra también métodos para la síntesis de los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos de uso de dichas composiciones para inducir la pérdida de peso y tratar la obesidad y trastornos relacionados con la obesidad.
EC2004005076A 2001-09-24 2004-04-22 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad ECSP045076A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32447301P 2001-09-24 2001-09-24

Publications (1)

Publication Number Publication Date
ECSP045076A true ECSP045076A (es) 2004-05-28

Family

ID=23263739

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005076A ECSP045076A (es) 2001-09-24 2004-04-22 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad

Country Status (25)

Country Link
US (2) US6960601B2 (es)
EP (1) EP1432691A1 (es)
JP (1) JP2005508384A (es)
KR (1) KR20040040472A (es)
CN (2) CN1599724A (es)
AR (1) AR036608A1 (es)
BR (1) BR0212986A (es)
CA (1) CA2459745A1 (es)
CO (1) CO5560560A2 (es)
EC (1) ECSP045076A (es)
GT (1) GT200200188A (es)
HN (1) HN2002000266A (es)
HR (1) HRP20040308A2 (es)
HU (1) HUP0402376A2 (es)
IL (1) IL160524A0 (es)
MA (1) MA27684A1 (es)
MX (1) MXPA04002037A (es)
NO (1) NO20041216L (es)
NZ (1) NZ531841A (es)
PE (1) PE20030547A1 (es)
PL (1) PL369326A1 (es)
RU (1) RU2004112770A (es)
UY (1) UY27450A1 (es)
WO (1) WO2003040107A1 (es)
ZA (1) ZA200403035B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7109216B2 (en) 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
MXPA05007114A (es) 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20060189591A1 (en) * 2003-04-21 2006-08-24 Daiichi Pharmaceutical Co., Ltd. Five-membered heterocyclic derivative
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
ES2386354T3 (es) 2003-07-29 2012-08-17 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
NZ546473A (en) 2003-10-08 2009-09-25 Bayer Schering Pharma Ag 1-amino-2-oxy-substituted tetrahydronaphthalene derivatives, methods for the production thereof, and their use as antiphlogistics
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
BRPI0415851A (pt) * 2003-10-24 2007-01-02 Solvay Pharm Gmbh utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
RU2367659C2 (ru) 2003-11-05 2009-09-20 Ф.Хоффманн-Ля Рош Аг Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
KR100843023B1 (ko) 2004-01-28 2008-07-01 에프. 호프만-라 로슈 아게 스피로-5환 화합물
US7173044B2 (en) * 2004-02-19 2007-02-06 Solvay Pharmaceuticals B.V. Imidazoline derivatives having CB1-antagonistic activity
CN1938281A (zh) * 2004-03-08 2007-03-28 惠氏公司 离子通道调节剂
WO2005086902A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
EP1722787A4 (en) * 2004-03-08 2007-09-26 Wyeth Corp ION CHANNEL MODULATORS
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1735287A1 (en) * 2004-04-03 2006-12-27 Astrazeneca AB Therapeutic agents
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
CA2564986A1 (en) 2004-05-10 2005-11-17 F. Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
US7524867B2 (en) * 2004-05-28 2009-04-28 Solvay Pharmaceuticals, B.V. Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
TW200616969A (en) * 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
WO2006060190A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Imidazole derivatives
WO2006060199A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Imidazole derivatives for the treatment of sexual dysfunction
JP2008526887A (ja) * 2005-01-10 2008-07-24 ユニバーシティ オブ コネチカット カンナビノイド受容体に作用する新規なヘテロピロール類似体
JP2008528700A (ja) * 2005-02-03 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
US8937184B2 (en) 2005-02-16 2015-01-20 Abbvie B.V. 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
DE102005017316A1 (de) * 2005-04-14 2006-10-19 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
AU2006297853B2 (en) 2005-05-12 2010-08-19 AbbVie Global Enterprises Ltd. Apoptosis promoters
ES2525217T3 (es) * 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
CA2618568A1 (en) * 2005-08-18 2007-02-22 F. Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
GB0518819D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
GB0518817D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
NZ566660A (en) 2005-09-30 2010-03-26 Banyu Pharma Co Ltd Aryl-substituted nitrogen-containing heterocyclic compound
EP1963313B1 (en) 2005-11-28 2012-11-14 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase (dgat)
EP1834948A1 (de) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7759352B2 (en) 2006-04-14 2010-07-20 Merck Sharp & Dohme Corp. Substituted imidazole-4-carboxamides as cholecystokinin-1 receptor modulators
MX2008013237A (es) * 2006-04-14 2009-03-06 Merck & Co Inc Imidazol 4-caroxamidas sustituidas como moduladores del receptor colecistoquinina-1.
DE602007008868D1 (de) * 2006-04-14 2010-10-14 Merck Sharp & Dohme Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
JP2010516768A (ja) 2007-01-26 2010-05-20 メルク・シャープ・エンド・ドーム・コーポレイション コレシストキニン−１レセプターモジュレーターとしての置換アミノピリミジン
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
GB2451629A (en) * 2007-08-06 2009-02-11 Univ Sheffield 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009314200B2 (en) 2008-11-17 2011-11-17 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3666758A1 (en) * 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
BR112012029026A2 (pt) 2010-05-13 2016-08-02 Amgen Inc composto heretocíclicos de nitrogênio úteis como inbidores pde10
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
KR20180125960A (ko) * 2016-03-15 2018-11-26 바이엘 크롭사이언스 악티엔게젤샤프트 동물 해충을 방제하기 위한 치환된 술포닐 아미드
MA46540A (fr) * 2016-10-12 2019-08-21 Res Triangle Inst Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations
TW201822637A (zh) * 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
RU2019117958A (ru) * 2016-11-18 2020-12-18 Мерк Шарп И Доум Корп. Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
JP2023501978A (ja) 2019-11-07 2023-01-20 バイエル・アクチエンゲゼルシヤフト 動物害虫駆除用の置換スルホニルアミド
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE140966C (es)
US5091405A (en) 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
DE3808071A1 (de) 1988-03-11 1989-09-21 Basf Ag Verfahren zur herstellung von acylierten imidazolen
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
DE4015535A1 (de) 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
WO1993014082A1 (en) 1992-01-13 1993-07-22 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5550147A (en) 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5565577A (en) 1992-09-23 1996-10-15 Smithkline Beecham Corporation Process for preparing 1-alkyaryl-2-alkyl-5-formylimidazole
ATE212985T1 (de) * 1993-11-30 2002-02-15 Searle & Co Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5519143A (en) 1994-09-19 1996-05-21 The Du Pont Merck Pharmaceutical Company Process for the isolation and purification of an imidazole stereoisomer from a mixture of stereoisomers by selective precipitation
AU740425B2 (en) * 1996-12-16 2001-11-01 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
BR9813835A (pt) 1997-12-22 2000-10-10 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
EP1177188B1 (en) 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
US6492516B1 (en) 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
DE60215139T2 (de) * 2001-01-26 2007-08-16 Chugai Seiyaku K.K. Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity

Also Published As

Publication number Publication date
US6960601B2 (en) 2005-11-01
KR20040040472A (ko) 2004-05-12
EP1432691A1 (en) 2004-06-30
CA2459745A1 (en) 2003-05-15
PL369326A1 (en) 2005-04-18
HUP0402376A2 (hu) 2005-02-28
HRP20040308A2 (en) 2006-08-31
BR0212986A (pt) 2004-08-17
JP2005508384A (ja) 2005-03-31
GT200200188A (es) 2003-06-25
CN1865248A (zh) 2006-11-22
CN1599724A (zh) 2005-03-23
US20040063691A1 (en) 2004-04-01
AR036608A1 (es) 2004-09-22
WO2003040107A8 (en) 2004-07-29
PE20030547A1 (es) 2003-08-18
CO5560560A2 (es) 2005-09-30
MA27684A1 (fr) 2006-01-02
ZA200403035B (en) 2005-04-21
IL160524A0 (en) 2004-07-25
WO2003040107A1 (en) 2003-05-15
US20050256167A1 (en) 2005-11-17
UY27450A1 (es) 2003-04-30
HN2002000266A (es) 2003-11-16
NO20041216L (no) 2004-05-05
MXPA04002037A (es) 2004-06-07
RU2004112770A (ru) 2005-10-10
NZ531841A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
UY27450A1 (es) Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
UY28374A1 (es) Agentes terapéuticos
UY28144A1 (es) Agentes terapéuticos
CR9034A (es) Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad
UY28752A1 (es) Agentes terapeuticos
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
UY28376A1 (es) Agentes terapéuticos
UY27360A1 (es) Compuestos heterobicíclicos sustituídos con triamida
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
ECSP034830A (es) Derivados sustituidos de la ciclohexano-1,4- diamina
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
UY28839A1 (es) Agentes terapeuticos
UY28150A1 (es) Agentes terapeuticos
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
UY28377A1 (es) Agentes terapeuticos
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists